Literature DB >> 27738358

Atomoxetine Induced Hypothermia: A Case Report.

Osman Abali1, Onat Yilmaz1.   

Abstract

Adverse drug reactions are common in drugs used during childhood and adolescence. Atomoxetine, a selective reuptake inhibitor, was introduced as a safe non-stimulant alternative treatment for attention deficit hyperactivity disorder. Described common side effects of atomoxetine include: headache, abdominal pain, decreased appetite, fatigue, nausea, vomiting and dizziness. In our case, we present an adolescent male who developed hypothermia under atomoxetine treatment. To our knowledge, this is the first report of a causal connection between atomoxetine intake and hypothermia. Because hypothermia is a life-threatening condition and can be treated when interfered immediately, clinicians should be aware of this adverse effect of atomoxetine.

Entities:  

Keywords:  ADHD; atomoxetine; hypothermia; side effect

Year:  2011        PMID: 27738358      PMCID: PMC5044483     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  5 in total

1.  Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Authors:  Frank P Bymaster; Jason S Katner; David L Nelson; Susan K Hemrick-Luecke; Penny G Threlkeld; John H Heiligenstein; S Michelle Morin; Donald R Gehlert; Kenneth W Perry
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

2.  Risk factors for hypothermia in psychiatric patients.

Authors:  D M Young
Journal:  Ann Clin Psychiatry       Date:  1996-06       Impact factor: 1.567

3.  Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine.

Authors:  S Yamawaki; H Lai; A Horita
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

Review 4.  ADHD in children, adolescents, and adults.

Authors:  Sreenivas Katragadda; Howard Schubiner
Journal:  Prim Care       Date:  2007-06       Impact factor: 2.907

Review 5.  Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Joshua Caballero; Milap C Nahata
Journal:  Clin Ther       Date:  2003-12       Impact factor: 3.393

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.